Editing Marburg virus disease (section)

== Research ==
Experimentally, recombinant [[Vesicular stomatitis virus|vesicular stomatitis Indiana virus]] (VSIV) expressing the glycoprotein of MARV has been used successfully in nonhuman primate models as post-exposure prophylaxis.<ref>{{Cite journal |last=Daddario-Dicaprio |first=K. M. |last2=Geisbert |first2=T. W. |last3=Ströher |first3=U. |last4=Geisbert |first4=J. B. |last5=Grolla |first5=A. |last6=Fritz |first6=E. A. |last7=Fernando |first7=L. |last8=Kagan |first8=E. |last9=Jahrling |first9=P. B. |last10=Hensley |first10=L. E. |last11=Jones |first11=S. M. |last12=Feldmann |first12=H. |year=2006 |title=Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: An efficacy assessment |url=https://apps.dtic.mil/sti/pdfs/ADA447898.pdf |url-status=live |journal=The Lancet |volume=367 |issue=9520 |pages=1399–1404 |doi=10.1016/S0140-6736(06)68546-2 |pmid=16650649 |s2cid=14039727 |archive-url=https://web.archive.org/web/20170927010820/http://www.dtic.mil/get-tr-doc/pdf?AD=ADA447898 |archive-date=2017-09-27 |access-date=2018-04-29}}</ref> A vaccine candidate has been effective in nonhuman primates.<ref>{{Cite journal |last=Woolsey |first=Courtney |last2=Cross |first2=Robert W. |last3=Agans |first3=Krystle N. |last4=Borisevich |first4=Viktoriya |last5=Deer |first5=Daniel J. |last6=Geisbert |first6=Joan B. |last7=Gerardi |first7=Cheryl |last8=Latham |first8=Theresa E. |last9=Fenton |first9=Karla A. |last10=Egan |first10=Michael A. |last11=Eldridge |first11=John H. |last12=Geisbert |first12=Thomas W. |last13=Mattasov |first13=Demetrius |year=2022 |title=A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge |journal=PLOS Neglected Tropical Diseases |volume=16 |issue=5 |pages=e0010433 |doi=10.1371/journal.pntd.0010433 |pmc=9182267 |pmid=35622847 |doi-access=free}}</ref> Experimental therapeutic regimens relying on [[antisense therapy|antisense technology]] have shown promise, with [[Morpholino|phosphorodiamidate morpholino oligomers]] (PMOs) targeting the MARV genome<ref>{{Cite journal |last=Warren |first=T. K. |last2=Warfield |first2=K. L. |last3=Wells |first3=J. |last4=Swenson |first4=D. L. |last5=Donner |first5=K. S. |last6=Van Tongeren |first6=S. A. |last7=Garza |first7=N. L. |last8=Dong |first8=L. |last9=Mourich |first9=D. V. |last10=Crumley |first10=S. |last11=Nichols |first11=D. K. |last12=Iversen |first12=P. L. |last13=Bavari |first13=S. |year=2010 |title=Advanced antisense therapies for postexposure protection against lethal filovirus infections |journal=Nature Medicine |volume=16 |issue=9 |pages=991–994 |doi=10.1038/nm.2202 |pmid=20729866 |s2cid=205387144}}</ref> New therapies from [[Sarepta Therapeutics|Sarepta]]<ref>{{Cite press release |title=Sarepta Therapeutics Announces Positive Safety Results from Phase I Clinical Study of Marburg Drug Candidate - Business Wire |date=2014-02-10 |url=http://www.businesswire.com/news/home/20140210005189/en/Sarepta-Therapeutics-Announces-Positive-Safety-Results-Phase |access-date=12 October 2014 |url-status=live |archive-url=https://web.archive.org/web/20180822113452/https://www.businesswire.com/news/home/20140210005189/en/Sarepta-Therapeutics-Announces-Positive-Safety-Results-Phase |archive-date=2018-08-22}}</ref> and Tekmira<ref>{{Cite web |date=2014-08-20 |title=Successful Marburg Virus Treatment Offers Hope for Ebola Patients |url=http://news.nationalgeographic.com/news/2014/08/140820-marburg-ebola-virus-treatment-monkey-africa/ |archive-url=https://web.archive.org/web/20140822032906/http://news.nationalgeographic.com/news/2014/08/140820-marburg-ebola-virus-treatment-monkey-africa/ |archive-date=August 22, 2014 |access-date=12 October 2014 |website=National Geographic}}</ref> have also been successfully used in humans as well as primates.